Glycosphingolipid Storage in Fabry Mice Extends Beyond Globotriaosylceramide and is Affected by ABCB1 Depletion

References

• Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276(21), 1163–1167 (1967).
   PubMed Web of Science ®Google Scholar
• Lidove O, Joly D, Barbey F et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int. J. Clin. Pract. 61(2), 293–302 (2007).
   PubMed Web of Science ®Google Scholar
• Motabar O, Sidransky E, Goldin E, Zheng W. Fabry disease – current treatment and new drug development. Curr. Chem. Genomics 4(1), 50–56 (2010).
   PubMedGoogle Scholar
• Vedder AC, Linthorst GE, van Breemen MJ et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J. Inherit. Metab. Dis. 30(1), 68–78 (2007).
   PubMed Web of Science ®Google Scholar
• Aerts JM. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl Acad. Sci. USA 105(8), 2812–2817 (2008).
   PubMed Web of Science ®Google Scholar
• Grösch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog. Lipid Res. 51(1), 50–62 (2012).
   PubMed Web of Science ®Google Scholar
• Mullen TD, Hannun YA, Obeid LM. Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem. J. 441(3), 789–802 (2012).
   PubMedGoogle Scholar
• Köberlin MS, Snijder B, Heinz LX et al. A conserved circular network of coregulated lipids modulates innate immune responses. Cell 162(1), 170–183 (2015).
   PubMed Web of Science ®Google Scholar
• Levy M, Futerman AH. Mammalian ceramide synthases. IUBMB Life 62(5), 347–356 (2010).
   PubMed Web of Science ®Google Scholar
• Ohshima T, Murray GJ, Swaim WD et al. α-Galactosidase A deficient mice: a model of fabry disease. Proc. Natl Acad. Sci. USA 94(6), 2540–2544 (1997).
   PubMed Web of Science ®Google Scholar
• Ohshima T, Schiffmann R, Murray GJ et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl Acad. Sci. USA 96(11), 6423–6427 (1999).
   PubMed Web of Science ®Google Scholar
• Dekker N, Van Dussen L, Hollak CEM et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118(16), e118–e127 (2011).
   PubMed Web of Science ®Google Scholar
• Xu S, Lun Y, Brignol N et al. Coformulation of a novel human α-galactosidase A with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry mice. Mol. Ther. 23(7), 1169–1181 (2015).
   PubMed Web of Science ®Google Scholar
• Kizhner T, Azulay Y, Hainrichson M et al. Characterization of a chemically modified plant cell culture expressed human α-galactosidase-A enzyme for treatment of Fabry disease. Mol. Genet. Metab. 114(2), 259–267 (2015).
   PubMed Web of Science ®Google Scholar
• Porubsky S, Jennemann R, Lehmann L, Gröne H-J. Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease. Cell Tissue Res. 358(1), 217–227 (2014).
   PubMed Web of Science ®Google Scholar
• Yokoi T, Kobayashi H, Shimada Y et al. Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease. J. Gene Med. 13(5), 262–268 (2011).
   PubMed Web of Science ®Google Scholar
• Shen J-S, Meng X-L, Wight-Carter M et al. Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice. Hum. Mol. Genet. 24(11), 3181–3191 (2015).
   PubMed Web of Science ®Google Scholar
• Moore DF, Ries M, Forget EL, Schiffmann R. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. Pharmacoeconomics 25(3), 201–208 (2007).
   PubMed Web of Science ®Google Scholar
• Vedder AC, Linthorst GE, Houge G et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2(7), e598 (2007).
   PubMed Web of Science ®Google Scholar
• Lidove O, West ML, Pintos-Morell G et al. Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet. Med. 12(11), 668–679 (2010).
   PubMed Web of Science ®Google Scholar
• Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MGW, Hollak CEM. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J. Inherit. Metab. Dis. 37(3), 341–352 (2014).
   PubMed Web of Science ®Google Scholar
• Kato A, Yamashita Y, Nakagawa S et al. 2,5-Dideoxy-2,5-imino-D-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg. Med. Chem. 18(11), 3790–3794 (2010).
   PubMed Web of Science ®Google Scholar
• Khanna R, Soska R, Lun Y et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol. Ther. 18(1), 23–33 (2010).
   PubMed Web of Science ®Google Scholar
• Yoshimitsu M, Higuchi K, Ramsubir S et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther. 14(3), 256–265 (2007).
   PubMed Web of Science ®Google Scholar
• Marshall J, Ashe KM, Bangari D et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE 5(11), e15033 (2010).
   PubMed Web of Science ®Google Scholar
• Mattocks M. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model. FEBS J. 273(9), 2064 (2006).
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385–427 (1993).
   PubMed Web of Science ®Google Scholar
• Ueda K. ABC proteins protect the human body and maintain optimal health. Biosci. Biotechnol. Biochem. 75(3), 401–409 (2011).
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84(21), 7735–7738 (1987).
   PubMed Web of Science ®Google Scholar
• Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb. Exp. Pharmacol. 201, 261–283 (2011).
   PubMedGoogle Scholar
• Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25(8), 423–429 (2004).
   PubMed Web of Science ®Google Scholar
• Molinari A, Cianfriglia M, Meschini S, Calcabrini A, Arancia G. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int. J. Cancer 59(6), 789–795 (1994).
   PubMed Web of Science ®Google Scholar
• Lala P, Ito S, Lingwood CA. Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 105- to 106-fold increased cell sensitivity to verocytotoxin. Role of P-glycoprotein in glycolipid synthesis. J. Biol. Chem. 275(9), 6246–6251 (2000).
   PubMed Web of Science ®Google Scholar
• Buton X, Hervé P, Kubelt J et al. Transbilayer movement of monohexosylsphingolipids in endoplasmic reticulum and Golgi membranes. Biochemistry 41(43), 13106–13115 (2002).
   PubMed Web of Science ®Google Scholar
• De Rosa MF, Sillence D, Ackerley C, Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 279(9), 7867–7876 (2004).
   PubMed Web of Science ®Google Scholar
• Eckford PDW, Sharom FJ. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 389(2), 517–526 (2005).
   PubMedGoogle Scholar
• Mizutani T, Hattori A. New horizon of MDR1 (P-glycoprotein) study. Drug Metab. Rev. 37(3), 489–510 (2005).
   PubMed Web of Science ®Google Scholar
• Coste H, Martel MB, Got R. Topology of glucosylceramide synthesis in Golgi membranes from porcine submaxillary glands. Biochim. Biophys. Acta 858(1), 6–12 (1986).
   PubMedGoogle Scholar
• Jeckel D, Karrenbauer A, Burger KNJ, Van Meer G, Wieland F. Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. J. Cell Biol. 117(2), 259–267 (1992).
   PubMed Web of Science ®Google Scholar
• Jeckel D. Lactosylceramide is synthesized in the lumen of the Golgi apparatus. FEBS Lett. 342(1), 91–96 (1994).
   PubMed Web of Science ®Google Scholar
• Yoshimitsu M, Sato T, Tao K et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc. Natl Acad. Sci. USA 101(48), 16909–16914 (2004).
   PubMed Web of Science ®Google Scholar
• Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. Clin. Chim. Acta. 112(2), 247–251 (1981).
   PubMed Web of Science ®Google Scholar
• Andrade J, Waters PJ, Singh RS et al. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin. J. Am. Soc. Nephrol. 3(1), 139–145 (2008).
   PubMed Web of Science ®Google Scholar
• Manwaring V, Boutin M, Auray-Blais C. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of fabry disease patients. Anal. Chem. 85(19), 9039–9048 (2013).
   PubMed Web of Science ®Google Scholar
• Auray-Blais C, Boutin M. Novel Gb3 isoforms detected in urine of Fabry disease patients: a metabolomic study. Curr. Med. Chem. 19(19), 3241–3252 (2012).
   PubMed Web of Science ®Google Scholar
• Petric M, Karmali MA, Richardson S, Cheung R. Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol. Lett. 41(1), 63–68 (1987).
   Web of Science ®Google Scholar
• Ottico E, Prinetti A, Prioni S et al. Dynamics of membrane lipid domains in neuronal cells differentiated in culture. J. Lipid Res. 44(11), 2142–2151 (2003).
   PubMed Web of Science ®Google Scholar
• Boyd B, Richardson S, Gariepy J. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter the action of the toxin. Infect. Immun. 59(3), 750–757 (1991).
   PubMed Web of Science ®Google Scholar
• Fisher RA. Frequency distribution of the values of the correlation coefficient in samples from an indefinitely large population. Biometrika 10(4), 507–521 (1915).
   Google Scholar
• D’Angelo G. Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature 449(7158), 62–67 (2007).
   PubMed Web of Science ®Google Scholar
• Halter D. Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J. Cell Biol. 179(1), 101–115 (2007).
   PubMed Web of Science ®Google Scholar
• Lingwood D, Binnington B, Rog T et al. Cholesterol modulates glycolipid conformation and receptor activity. Nat. Chem. Biol. 7(5), 260–262 (2011).
   PubMed Web of Science ®Google Scholar
• Taguchi A, Maruyama H, Nameta M et al. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochem. J. 456(3), 373–83 (2013).
   PubMedGoogle Scholar
• Kuchar L, Faltyskova H, Krasny L et al. Fabry disease: renal sphingolipid distribution in the α-Gal A knockout mouse model by mass spectrometric and immunohistochemical imaging. Anal. Bioanal. Chem. 407(8), 2283–2291 (2014).
   PubMed Web of Science ®Google Scholar
• Durant B, Forni S, Sweetman L et al. Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J. Lipid Res. 52(9), 1742–1746 (2011).
   PubMed Web of Science ®Google Scholar
• Aureli M, Grassi S, Prioni S, Sonnino S, Prinetti A. Lipid membrane domains in the brain. Biochim. Biophys. Acta 1851(8), 1006–1016 (2015).
   PubMed Web of Science ®Google Scholar
• Lingwood CA, Binnington B, Manis A, Branch DR. Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect. FEBS Lett. 584(9), 1879–86 (2010).
   PubMed Web of Science ®Google Scholar
• Nutikka A, Lingwood C. Generation of receptor-active, globotriaosyl ceramide/cholesterol lipid “rafts” in vitro: A new assay to define factors affecting glycosphingolipid receptor activity. Glycoconj. J. 20(1), 33–38 (2004).
   PubMed Web of Science ®Google Scholar
• Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284(1), 31–53 (2003).
   PubMed Web of Science ®Google Scholar
• Yoon S-J. Epidermal growth factor receptor tyrosine kinase is modulated by GM3 interaction with N-linked GlcNAc termini of the receptor. Proc. Natl Acad. Sci. USA 103(50), 18987–18991 (2006).
   PubMed Web of Science ®Google Scholar
• Kabayama K, Sato T, Saito K et al. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc. Natl Acad. Sci. USA 104(34), 13678–13683 (2007).
   PubMed Web of Science ®Google Scholar
• Fuller M, Sharp PC, Rozaklis T et al. Urinary lipid profiling for the identification of fabry hemizygotes and heterozygotes. Clin. Chem. 51(4), 688–694 (2005).
   PubMed Web of Science ®Google Scholar
• Paschke E, Fauler G, Winkler H et al. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study. Am. J. Kidney Dis. 57(5), 673–681 (2011).
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Pandey A. The Yin and Yang of lactosylceramide metabolism: implications in cell function. Biochim. Biophys. Acta 1780(3), 370–382 (2008).
   PubMed Web of Science ®Google Scholar
• D’Angelo G, Uemura T, Chuang C-C et al. Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi. Nature 501(7465), 116–120 (2013).
   PubMed Web of Science ®Google Scholar
• Yamaji T, Nishikawa K, Hanada K. Transmembrane BAX Inhibitor Motif containing (TMBIM) family proteins perturbs a trans-Golgi network enzyme, Gb3 synthase, and reduces Gb3 biosynthesis. J. Biol. Chem. 285(46), 35505–35518 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou H, Ma H, Wei W et al. B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1. Cell Death Dis. 4, e654 (2013).
   PubMed Web of Science ®Google Scholar
• Liu Y-Y, Gupta V, Patwardhan GA et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signaling. Mol. Cancer 9, 145 (2010).
   PubMed Web of Science ®Google Scholar
• Gouaze-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta 1758(12), 2096–2103 (2006).
   PubMed Web of Science ®Google Scholar
• Gouazé V, Liu Y-Y, Prickett CS, Yu JY, Giuliano AE, Cabot MC. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 65(9), 3861–3867 (2005).
   PubMed Web of Science ®Google Scholar
• Gouazé V, Yu JY, Bleicher RJ et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther. 3(5), 633–639 (2004).
   PubMed Web of Science ®Google Scholar
• Veldman RJ, Sietsma H, Klappe K, Hoekstra D, Kok JW. Inhibition of P-glycoprotein activity and chemosensitization of multidrug-resistant ovarian carcinoma 2780AD cells by hexanoylglucosylceramide. Biochem. Biophys. Res. Commun. 266(2), 492–496 (1999).
   PubMed Web of Science ®Google Scholar
• Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res. 18(1B), 475–480 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu X, Li J et al. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells. J. Surg. Oncol. 104(5), 466–471 (2011).
   PubMed Web of Science ®Google Scholar
• De Rosa MF. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. J. Biol. Chem. 283(8), 4501 (2008).
   PubMed Web of Science ®Google Scholar
• Chai L, McLaren RP, Byrne A et al. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int. J. Oncol. 38(3), 701–711 (2011).
   PubMed Web of Science ®Google Scholar
• Sakai K, Akiyama M, Sugiyama-Nakagiri Y, McMillan JR, Sawamura D, Shimizu H. Localization of ABCA12 from Golgi apparatus to lamellar granules in human upper epidermal keratinocytes. Exp. Dermatol. 16(11), 920–926 (2007).
   PubMed Web of Science ®Google Scholar